{
    "url_original": "https://www.wsj.com/articles/fda-advisers-say-agency-shouldnt-approve-china-developed-cancer-drug-now-11644524951?mod=business_featst_pos3",
    "url": "fda-advisers-say-agency-shouldnt-approve-china-developed-cancer-drug-now-11644524951",
    "title": "FDA Advisers Say Agency Shouldn’t Approve China-Developed Cancer Drug Now",
    "sub_head": "The experts voted 14 to 1 that Eli Lilly and its Chinese partner conduct more testing before the FDA approves the lung-cancer immunotherapy",
    "category_1": "Health",
    "image_1_url": "https://images.wsj.net/im-483943?width=860&height=573",
    "image_1": "im-483943.jpg",
    "time": "2022-02-10 15:29:00",
    "body": "A panel advising U.S. drug regulators said  Eli Lilly and Co.  and its Chinese partner should conduct more studies of a proposed new lung-cancer drug before approval, citing concerns about the medicine’s testing in China.<br />The advisers voted 14 to 1 on Thursday to recommend the additional testing after Food and Drug Administration officials said a Chinese study of the drug had significant shortcomings and its results weren’t applicable to U.S. patients."
}